Key terms
About VTVT
vTv Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. Its products target the treatment of central nervous system disorders, diabetes and metabolic disorders, inflammation, and cancer. It offers Azeliragon, TTP399, TTP273, HPP593, HPP737, and the Nrf2/Bach1 program. The company was founded on April 2, 2015 and is headquartered in High Point, NC.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest VTVT news
Apr 10
5:14pm ET
vTv Therapeutics files $250M mixed securities shelf
Mar 14
8:12am ET
vTv Therapeutics Appoints Anne Phillips, Reshuffles Board Committees
Mar 13
8:05am ET
vTv Therapeutics expects cash to fund operations through Phase 3 study data
Mar 13
8:04am ET
vTv Therapeutics reports Q4 EPS ($1.67) vs. ($2.28) last year
Mar 05
8:23am ET
vTv Therapeutics Enhances Investor Communication with Update
Mar 04
8:04am ET
vTv Therapeutics announces FDA submission for Phase 3 study of cadisegliatin
Mar 01
11:04am ET
Biotech Alert: Searches spiking for these stocks today
Feb 28
11:26am ET
vTv Therapeutics trading resumes
Feb 28
11:16am ET
vTv Therapeutics trading halted, volatility trading pause
Feb 28
8:22am ET
vTv Therapeutics Secures $51M Through Private Placement and Warrants
Feb 28
8:12am ET
vTv Therapeutics reduces board to seven members from nine
Jan 26
11:25am ET
Biotech Alert: Searches spiking for these stocks today
Jan 25
11:38am ET
Biotech Alert: Searches spiking for these stocks today
Jan 25
11:38am ET
Biotech Alert: Searches spiking for these stocks today
No recent press releases are available for VTVT
VTVT Financials
Key terms
Ad Feedback
VTVT Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
VTVT Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range